vorinostat has been researched along with Salivary Gland Neoplasms in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is a histone deacetylase inhibitor (HDACi)." | 2.84 | A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. ( Barrett, MT; Boerner, SA; Casetta, L; Chao, J; Chen, A; Goncalves, PH; Hansen, AR; Heilbrun, LK; Kummar, S; Lenkiewicz, E; LoRusso, PM; Malasi, S; Piekarz, RL; Pilat, MJ; Siu, LL; Smith, DW; Sukari, AW, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rodriguez, CP | 1 |
| Wu, QV | 1 |
| Voutsinas, J | 1 |
| Fromm, JR | 1 |
| Jiang, X | 1 |
| Pillarisetty, VG | 1 |
| Lee, SM | 1 |
| Santana-Davila, R | 1 |
| Goulart, B | 1 |
| Baik, CS | 1 |
| Chow, LQM | 1 |
| Eaton, K | 1 |
| Martins, R | 1 |
| Goncalves, PH | 1 |
| Heilbrun, LK | 1 |
| Barrett, MT | 1 |
| Kummar, S | 1 |
| Hansen, AR | 1 |
| Siu, LL | 1 |
| Piekarz, RL | 1 |
| Sukari, AW | 1 |
| Chao, J | 1 |
| Pilat, MJ | 1 |
| Smith, DW | 1 |
| Casetta, L | 1 |
| Boerner, SA | 1 |
| Chen, A | 1 |
| Lenkiewicz, E | 1 |
| Malasi, S | 1 |
| LoRusso, PM | 1 |
| Wagner, VP | 1 |
| Martins, MD | 1 |
| Martins, MAT | 1 |
| Almeida, LO | 1 |
| Warner, KA | 1 |
| Nör, JE | 1 |
| Squarize, CH | 1 |
| Castilho, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies[NCT02538510] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2015-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Kaplan Meier methods will be used to estimate progression free survival. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Months (Mean) |
|---|---|
| Head and Neck Squamous Cell Carcinoma | 12.6 |
| Salivary Gland Carcinoma | 14.0 |
Toxicities will be summarized as the number and percentage of patients with each type of toxicity, per Criteria for Adverse Events version 4.0 (NCT02538510)
Timeframe: Up to 30 days after the completion of study treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | ALT increase | Anorexia | Arthiritis | AST increase | Cough | Increased Creatinine | Dermatitis | Diarrhea | Fever with leukocytosis | Fatigue | Hyponatremia | Hypothyroidism | Colitis and Ileitis | Malaise | Nausea | Nephritis | Pneumonitis | Neuritis | Tracheitis/Epiglottitis | Vomiting | |
| Head and Neck Squamous Cell Carcinoma | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Salivary Gland Carcinoma | 1 | 1 | 1 | 1 | 1 | 0 | 5 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 2 |
Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| partial response | stable disease | progressive disease | |
| Head and Neck Squamous Cell | 8 | 8 | 5 |
| Salivary Gland Carcinoma | 4 | 13 | 6 |
2 trials available for vorinostat and Salivary Gland Neoplasms
| Article | Year |
|---|---|
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2020 |
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Chromatin Assembly and Disassembly; Exome Sequencing; Female | 2017 |
1 other study available for vorinostat and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Emetine; Histone Deacetylase Inh | 2018 |